Brief: Amphastar Pharmaceuticals Enteres License Agreement With Nanjing Anji Biotechnology
12/08/2025 11:47
Aug 12 (Reuters) - Amphastar Pharmaceuticals Inc AMPH.O: AMPHASTAR PHARMACEUTICALS INC - ON AUGUST 8, ENTERED LICENSE AGREEMENT WITH NANJING ANJI BIOTECHNOLOGY - SEC FILING AMPHASTAR PHARMACEUTICALS INC - TO PAY UP TO $267 MILLION IN MILESTONE PAYMENTS - SEC FILING AMPHASTAR PHARMACEUTICALS INC - PAYS $6 MILLION TO ANJI UPON AGREEMENT SIGNING - SEC FILING Further company coverage: AMPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amphastar Pharmaceuticals
See all newsAmphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Amphastar Pharmaceuticals Q2 EPS USD 0.67
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Amphastar rises after FDA approves new over-the-counter overdose spray